Savara Inc Net Assets
Savara Inc net assets. Based on the latest financial reports, Savara Inc (SVRA) has net assets worth $143.66 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($192.14 Million) and total liabilities ($48.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore SVRA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $143.66 Million |
| % of Total Assets | 74.77% |
| Annual Growth Rate | 11.1% |
| 5-Year Change | 40.58% |
| 10-Year Change | N/A |
| Growth Volatility | 119.73 |
Net Assets of Savara Inc (2000–2025)
Net assets of Savara Inc from 2000 to 2025. This chart illustrates how Savara Inc's net assets have evolved over time, based on quarterly financial data. See Savara Inc (SVRA) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Savara Inc (2000–2025)
The table below shows the annual net assets of Savara Inc from 2000 to 2025. For live market cap and overall valuation, see Savara Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $203.13 Million | +18.48% |
| 2024-12-31 | $171.45 Million | +22.14% |
| 2023-12-31 | $140.37 Million | +30.24% |
| 2022-12-31 | $107.78 Million | -25.41% |
| 2021-12-31 | $144.50 Million | +124.44% |
| 2020-12-31 | $64.38 Million | -36.69% |
| 2019-12-31 | $101.70 Million | -- |
| 2018-12-31 | $0.00 | -- |
| 2017-12-31 | $119.31 Million | +432.57% |
| 2016-12-31 | $-35.88 Million | -250.17% |
| 2015-12-31 | $23.89 Million | -59.27% |
| 2014-12-31 | $58.66 Million | +22.70% |
| 2013-12-31 | $47.81 Million | +14.39% |
| 2012-12-31 | $41.79 Million | -26.39% |
| 2011-12-31 | $56.78 Million | +112.77% |
| 2010-12-31 | $26.69 Million | +299.87% |
| 2009-12-31 | $6.67 Million | +11.31% |
| 2008-12-31 | $6.00 Million | -80.68% |
| 2007-12-31 | $31.03 Million | +55.50% |
| 2006-12-31 | $19.96 Million | +354.93% |
| 2005-12-31 | $-7.83 Million | -163.18% |
| 2004-12-31 | $12.39 Million | +200.71% |
| 2003-12-31 | $4.12 Million | +583.19% |
| 2002-12-31 | $-852.73K | -33.56% |
| 2001-12-31 | $-638.49K | -104.37% |
| 2000-12-31 | $14.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Savara Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60038277800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Savara Inc Net Assets Breakdown (December 2025)
Savara Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $204.00K | 0.10% |
| Other Comprehensive Income | $-87.00K | -0.04% |
| Other Components | $811.10 Million | 399.30% |
| Total Equity | $203.13 Million | 100.00% |
Savara Inc Competitors by Market Cap
The table below lists competitors of Savara Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
4DMEDICAL Ltd
AU:4DX
|
$990.61 Million |
|
Ategrity Specialty Insurance Company Holdings
NYSE:ASIC
|
$990.91 Million |
|
Wuxi Chipown Micro-electronics Ltd
SHG:688508
|
$991.15 Million |
|
Heritage Insurance Hldgs Inc
NYSE:HRTG
|
$991.16 Million |
|
Tianjin You Fa Steel Pipe Group Stock Co Ltd
SHG:601686
|
$990.24 Million |
|
Gracell Biotechnologies Inc.
NASDAQ:GRCL
|
$989.87 Million |
|
Max Zipper Co Ltd
TWO:8932
|
$989.63 Million |
|
Starlake Bioscience Co Inc Zhaoqing Guangdong
SHG:600866
|
$989.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Savara Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 171,449,000 to 203,133,000, a change of 31,684,000 (18.5%).
- Net loss of 118,837,000 reduced equity.
- Share repurchases of 5,140,000 reduced equity.
- New share issuances of 140,228,000 increased equity.
- Other comprehensive income increased equity by 663,000.
- Other factors increased equity by 14,770,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-118.84 Million | -58.5% |
| Share Repurchases | $5.14 Million | -2.53% |
| Share Issuances | $140.23 Million | +69.03% |
| Other Comprehensive Income | $663.00K | +0.33% |
| Other Changes | $14.77 Million | +7.27% |
| Total Change | $- | 18.48% |
Book Value vs Market Value Analysis
This analysis compares Savara Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.86x to 5.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $0.30 | $4.82 | x |
| 2001-12-31 | $-76.59 | $4.82 | x |
| 2002-12-31 | $-95.33 | $4.82 | x |
| 2003-12-31 | $212.97 | $4.82 | x |
| 2004-12-31 | $427.51 | $4.82 | x |
| 2005-12-31 | $-228.99 | $4.82 | x |
| 2006-12-31 | $472.05 | $4.82 | x |
| 2007-12-31 | $604.03 | $4.82 | x |
| 2008-12-31 | $116.25 | $4.82 | x |
| 2009-12-31 | $100.09 | $4.82 | x |
| 2010-12-31 | $141.72 | $4.82 | x |
| 2011-12-31 | $141.06 | $4.82 | x |
| 2012-12-31 | $61.41 | $4.82 | x |
| 2013-12-31 | $43.70 | $4.82 | x |
| 2014-12-31 | $33.54 | $4.82 | x |
| 2015-12-31 | $10.31 | $4.82 | x |
| 2016-12-31 | $-10.72 | $4.82 | x |
| 2017-12-31 | $6.81 | $4.82 | x |
| 2018-12-31 | $3.25 | $4.82 | x |
| 2019-12-31 | $2.54 | $4.82 | x |
| 2020-12-31 | $1.09 | $4.82 | x |
| 2021-12-31 | $1.08 | $4.82 | x |
| 2022-12-31 | $0.71 | $4.82 | x |
| 2023-12-31 | $0.85 | $4.82 | x |
| 2024-12-31 | $0.87 | $4.82 | x |
| 2025-12-31 | $0.91 | $4.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Savara Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (-58.50%) is above the historical average (-68.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -25.33% | 0.00% | 0.00x | 1.02x | $-5.16 Million |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.28 Million |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.02 Million |
| 2003 | -56.60% | 0.00% | 0.00x | 1.04x | $-2.74 Million |
| 2004 | -54.08% | 0.00% | 0.00x | 1.10x | $-7.94 Million |
| 2005 | 0.00% | -4995.91% | 0.02x | 0.00x | $-24.00 Million |
| 2006 | -146.97% | 0.00% | 0.00x | 2.65x | $-31.33 Million |
| 2007 | -71.35% | -4428.41% | 0.01x | 1.11x | $-25.25 Million |
| 2008 | -444.48% | -5329.50% | 0.05x | 1.79x | $-27.25 Million |
| 2009 | -169.70% | -3775.02% | 0.03x | 1.35x | $-11.99 Million |
| 2010 | -31.67% | -1728.35% | 0.02x | 1.07x | $-11.12 Million |
| 2011 | -23.35% | 0.00% | 0.00x | 1.09x | $-18.94 Million |
| 2012 | -37.23% | 0.00% | 0.00x | 1.12x | $-19.74 Million |
| 2013 | -44.93% | 0.00% | 0.00x | 1.16x | $-26.26 Million |
| 2014 | -48.93% | -1854134.37% | 0.00x | 1.20x | $-34.57 Million |
| 2015 | -166.78% | -73781481.48% | 0.00x | 2.27x | $-42.23 Million |
| 2016 | 0.00% | -2730.75% | 0.01x | 0.00x | $-7.34 Million |
| 2017 | -24.97% | 0.00% | 0.00x | 1.34x | $-41.73 Million |
| 2018 | -56.84% | 0.00% | 0.00x | 1.41x | $-72.34 Million |
| 2019 | -76.87% | 0.00% | 0.00x | 1.34x | $-88.34 Million |
| 2020 | -77.06% | -19305.45% | 0.00x | 1.52x | $-56.05 Million |
| 2021 | -29.77% | -4301400.00% | 0.00x | 1.22x | $-57.46 Million |
| 2022 | -35.40% | 0.00% | 0.00x | 1.30x | $-48.93 Million |
| 2023 | -38.97% | 0.00% | 0.00x | 1.26x | $-68.74 Million |
| 2024 | -55.92% | 0.00% | 0.00x | 1.24x | $-113.03 Million |
| 2025 | -58.50% | 0.00% | 0.00x | 1.25x | $-139.15 Million |
Industry Comparison
This section compares Savara Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Savara Inc (SVRA) | $143.66 Million | -25.33% | 0.34x | $990.32 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, P… Read more